

1 **Immunohistochemical Profiling of Histone Modification Biomarkers Identifies**  
2 **Subtype-Specific Epigenetic Signatures and Potential Drug Targets in Breast Cancer**

3 Zirong Huo<sup>1</sup>, Sitong Zhang<sup>1</sup>, Guodong Su<sup>1</sup>, Yu Cai<sup>1</sup>, Rui Chen<sup>1</sup>, Mengju Jiang<sup>1</sup>, Dongyan  
4 Yang<sup>1</sup>, Shengchao Zhang<sup>1</sup>, Yuyan Xiong<sup>1</sup>, Xi Zhang<sup>1,2\*</sup>

5

6 1 School of Life Science, Northwest University, Xi'an, Shaanxi 710069, China

7 2 School of Professional Studies, Northwestern University, Evanston, IL 60201, US

8 \* Corresponding author

9

10 Zirong Huo: [h zr1661864339@163.com](mailto:h zr1661864339@163.com)

11 Sitong Zhang: [zstongoo@163.com](mailto:zstongoo@163.com)

12 Guodong Su: [1938824365@qq.com](mailto:1938824365@qq.com)

13 Yu Cai: [caiyu1316@163.com](mailto:caiyu1316@163.com)

14 Rui Chen: [yourangle@126.com](mailto:yourangle@126.com)

15 Mengju Jiang: [1441564131@qq.com](mailto:1441564131@qq.com)

16 Dongyan Yang: [202322544@stumail.nwu.edu.cn](mailto:202322544@stumail.nwu.edu.cn)

17 Shengchao Zhang: [zhangshengchao0601@163.com](mailto:zhangshengchao0601@163.com)

18 Yuyan Xiong: [yuyan.xiong@nwu.edu.cn](mailto:yuyan.xiong@nwu.edu.cn)

19 Xi Zhang: [xzhang19@nwu.edu.cn](mailto:xzhang19@nwu.edu.cn)

20

21 **Abstract**

22 **Background:** Breast cancer (BC) subtypes exhibit distinct epigenetic landscapes, with  
23 triple-negative breast cancer (TNBC) lacking effective targeted therapies. This study  
24 investigates histone biomarkers and therapeutic vulnerabilities across BC subtypes.

25 **Methods:** Immunohistochemical profiling of >20 histone biomarkers, including histone  
26 modifications, modifiers and oncohistone mutations was conducted on a discovery cohort  
27 and a validation cohort of BC tissues, healthy controls and cell line models.  
28 Transcriptomic and cell growth analyses were conducted to evaluate the effects of the  
29 small-molecule G9a inhibitor in diverse BC models. **Results:** Key histone biomarkers,  
30 including H3K9me2, H3K36me2, and H3K79me, were differentially expressed across  
31 BC subtypes. H3K9me2 emerged as an independent predictor for distinguishing TNBC  
32 from other less aggressive BC subtypes, with elevated expression correlating with higher  
33 tumor grade and stage. G9a inhibition impaired cell proliferation and modulated  
34 epithelial-mesenchymal transition pathways, with the strongest impact in basal-like  
35 TNBC. Disruption of oncogene and tumor suppressor regulation (e.g., TP53, SATB1)  
36 was observed in TNBC. **Conclusion:** This study highlights G9a's context-dependent roles  
37 in BC, supporting its potential as a therapeutic target. Findings provide a foundation for  
38 subtype-specific epigenetic therapies to improve outcomes in aggressive BC subtypes.

39 **Keyword**

40 Histone Modification, Immunohistochemical Profiling, Triple-negative Breast Cancer,  
41 G9a Inhibitor

42

### 43 **Clinical Perspective**

- 44       • This study was undertaken to explore the epigenetic landscape of breast cancer  
45       subtypes, focusing on histone modifications and their therapeutic potential,  
46       particularly through targeting G9a, a histone methyltransferase.
- 47       • The study identified subtype-specific histone biomarkers, with H3K9me2  
48       emerging as a key marker distinguishing TNBC from other less aggressive  
49       subtypes. G9a inhibition demonstrated robust anti-cancer effects, including cell  
50       proliferation impairment and disruption of oncogenic pathways, particularly in  
51       TNBC models.
- 52       • These findings provide compelling evidence for the development of subtype-  
53       specific epigenetic therapies targeting G9a and similar regulators, highlighting  
54       their potential to reshape the treatment landscape for TNBC and improve patient  
55       outcomes.

56  
57

## 58 **Introduction**

59 Histones, as the core components of chromatin, undergo chemical modifications that  
60 regulate gene expression and are intimately linked to cancer development[1]. Histone  
61 modifications such as methylation and acetylation act as pivotal regulators of gene  
62 activity, influencing transcriptional regulation and tumor progression depending on their  
63 type and genomic context[2, 3]. For instance, H3K4me2 is a mark of active transcription,  
64 typically found at promoters of genes primed for expression. Conversely, H3K9me2 is  
65 associated with transcriptional repression and heterochromatin formation, silencing genes  
66 that may drive tumorigenesis. However, the loss of H3K9me2 can paradoxically activate  
67 oncogenes, contributing to cancer progression.

68 BC is a highly heterogeneous disease, classified into distinct molecular subtypes based on  
69 the expression of classic biomarkers such as Estrogen Receptor (ER), Progesterone  
70 Receptors (PR) and Human Epidermal Growth Factor Receptor 2 (HER2)[4]. Among  
71 these, TNBC poses the greatest clinical challenge due to its aggressive nature and the  
72 absence of well-defined therapeutic targets. Bridging the treatment gaps in TNBC  
73 necessitates innovative approaches, particularly those focusing on its unique molecular  
74 and epigenetic characteristics[5]. Aberrations in histone modifications in cancer can vary  
75 significantly, even within the same cancer type. Research has demonstrated that different  
76 molecular subtypes of BC (e.g., luminal A and TNBC) exhibit distinct patterns of histone  
77 modifications, reflecting subtype-specific epigenetic landscapes[6]. Although evidence  
78 from cell line studies have highlighted that TNBC is the molecular subtype that most  
79 closely associated with distinct histone modification patterns[7, 8], research focusing on  
80 human tissue remains limited. This gap underscores the need for studies using patient-

81 derived samples to validate findings from in vitro models and to explore the clinical  
82 relevance of these epigenetic alterations in tumor progression.

83 The unique histone modification patterns of TNBC, once fully characterized, may  
84 distinguish it from subtypes like luminal A and HER2-enriched breast cancers,  
85 highlighting new possibilities for subtype-specific therapies[9]. Current epigenetic  
86 treatments, including DNA methyltransferase (DNMT) and histone deacetylase (HDAC)  
87 inhibitors, show clinical promise[10]. Histone methyltransferase (HMT) inhibitors  
88 correspond to the third generation of epigenetic drugs capable of writing or deleting  
89 epigenetic information[11, 12]. EZH2 inhibitor, targeting H3K27me3, is the first and only  
90 HMT inhibitor that approved by FDA in 2020 for the treatment of certain cancers[13, 14].  
91 Emerging targets like H3K79me1/2/3 (DOT1L inhibitors) and H3K9me2 (G9a inhibitors)  
92 are showing potential in preclinical studies of breast cancer[15-17].

93 In this study, the global expression of histone modifications, histone modifiers, and  
94 oncohistone mutations was characterized in BC tissues using immunohistochemical (IHC)  
95 staining. Expression patterns were validated across two independent cohorts and  
96 compared to those in healthy tissue samples and BC cell lines. Subtype-specific histone  
97 modifications were identified, with several significant ones showing strong associations  
98 with the TNBC subtype, tumor grade, and stage. Treatment with a small-molecule  
99 epigenetic inhibitor significantly impaired cell growth in both estrogen receptor-positive  
100 and -negative cell lines. Transcriptomic and pathway analyses further confirmed distinct  
101 responses between the two cell line types. Together, these findings highlight specific  
102 histone modifications as critical markers and drivers of advanced or accelerated breast  
103 cancer progression and establish histone modifiers as promising therapeutic targets in BC.

104 **Method**

105 **Study Design**

106 To identify and evaluate the potential of 21 pathological biomarkers in breast cancer, this  
107 study used tissue microarray technology, allowing for high-throughput molecular analysis  
108 of 196 tissue samples from a discovery cohort of 98 breast cancer patients (Fig. 1). The  
109 IHC profiling results of TNBC were then validated by additional 20 tissue blocks from a  
110 validation cohort of 20 TNBC patients. Eligible participants of both cohorts were women  
111 aged 35-70 years with a first primary diagnosis of breast cancer (Table 1). The  
112 distributions of clinical characteristics and traditional pathological biomarker results are  
113 shown for both the discovery and validation cohorts, as provided by the commercial  
114 vendors of BC tissues. Based on IHC assessments of ER, PR, HER2, and Ki-67, breast  
115 cancer samples in this study were classified into 79 luminal A cases, 53 luminal B cases,  
116 23 HER2-enriched cases, and 41 TNBC cases in the discovery cohort, as well as 20  
117 TNBC cases in the validation cohort. Histone biomarker signatures identified from tissue  
118 samples were subsequently evaluated in BC cell lines. To explore their functional  
119 relevance, the selected HMT inhibitor, G9a inhibitor UNC0642, was applied to assess its  
120 effects on cell proliferation, impacted gene expression and signaling pathways. All study  
121 procedures were approved by the Institutional Ethics Committee and the Institutional  
122 Review Board of Northwest University (approval number: 200,402,001).

123 **Tissue Specimens**

124

125 We collected 216 tissue samples from commercial sources for this study. A high-density  
126 breast cancer tissue microarray (chip number F1961101 B06-F1961101 B25) was  
127 purchased from Xi'an Bioaitech Co., Ltd. Each chip included two 1-mm tissue cores  
128 from 98 patients with various molecular subtypes, forming a discovery cohort of 196  
129 samples. A validation cohort was established using 20 TNBC tissue slides procured from  
130 Shanghai Xinchao Co., Ltd. (sample codes listed in Table S4). Clinical characteristics and  
131 biomarker data were available for all tissue samples (Table 1).

### 132 **Cell Culture**

133 Three breast cancer cell lines—MCF-7 (luminal A), MDA-MB-231 (claudin-low TNBC),  
134 and MDA-MB-468 (basal-like TNBC)—and two T-lymphocytic leukemia cell lines  
135 (HPB-ALL and LOUCY) were used in this study. Origin and catalogue number of cell  
136 lines are listed in Table S4. Three BC cell lines were cultured in Dulbecco's modified  
137 Eagle's medium (DMEM). HPB-ALL and LOUCY cells were cultured in RPMI-1640. In  
138 both media, 10% fetal bovine serum and 1% penicillin/streptomycin were added. The  
139 above cells were grown in a humidified 5% CO<sub>2</sub> incubator at 37°C. For estrogen  
140 treatment, cells were starved in phenol red-free DMEM supplemented with 10%  
141 charcoal-stripped FBS for 2 days, and 73.4 nM estrogen were added to the medium (3  
142 and 6 h for gene expression studies, and 6 h for immunocytochemical (ICC) experiments)  
143 before the cells were collected. The detailed list of reagents and kits used in the method  
144 can be found in Table S4.

### 145 **IHC and ICC**

146 IHC analysis was performed using the streptavidin-biotin-peroxidase complex method to  
147 evaluate 20 histone biomarks (including H3) of interest. Tissue chips and slides were  
148 processed by deparaffinization, antigen retrieval, blocking with goat serum, and  
149 incubation with primary antibodies overnight at 4°C. Secondary antibodies and DAB  
150 were used for detection, followed by counterstaining and mounting. Anti-H3 served as a  
151 control. Details of antibodies, reagents and kits are provided in Table S4. ICC was  
152 performed using the same principles as IHC. Cells were fixed in 4% paraformaldehyde,  
153 permeabilized with 0.25% Triton X-100, and blocked with 10% goat serum. Primary  
154 antibodies were incubated overnight, followed by secondary antibody incubation and  
155 DAB detection.

#### 156 **Cell Viability and Proliferation Assay**

157 Cell viability was assessed using the Cell Counting Kit-8 (CCK-8). Cells were seeded in  
158 96-well plates ( $5 \times 10^3$ /well), treated with UNC0642 or DMSO (Control), and incubated.  
159 After treatment, 10  $\mu$ L CCK-8 solution was added, and OD450 was measured. For  
160 proliferation assays, cells were treated with 2  $\mu$ M UNC0642 or DMSO and analyzed over  
161 six days using the same method. The detailed list of reagents and kits used in the method  
162 can be found in Table S4.

#### 163 **Western Blotting**

164 Proteins from BC cells, which were treated with 2  $\mu$ M UNC0642 or DMSO for 48 h and  
165 were extracted using RIPA buffer, quantified using the BCA assay, and separated by SDS-  
166 PAGE. After transfer to PVDF membranes, blots were incubated with primary and



167 secondary antibodies. Signals were detected using enhanced chemiluminescence, with H3  
168 as a loading control. Antibodies, reagents and kits details are listed in Table S4.

### 169 **RNA isolation and Sequencing**

170 Total RNA from BC cells collected after 4 days of treatment with 2  $\mu$ M UNC0642 or  
171 DMSO was extracted using Trizol and assessed for purity and integrity. RNAseq libraries  
172 were prepared using the TruSeq RNA Sample Prep Kit and sequenced on an Illumina  
173 NovaSeq 6000 platform. Clean reads were analyzed using STAR aligner and DESeq2 to  
174 identify differentially expressed genes (DEGs). Genes in breast cancer cell lines that  
175 displayed at least one-fold difference in gene expression between comparison groups  
176 (fold change  $> 1$  or  $< -1$ , FDR  $p < 0.05$ ) were considered significant DEGs and carried  
177 forward in the analysis. Pathway and gene ontology (GO) enrichment analysis was  
178 performed via an integrated platform KOBAS 3.0 and GSEA using MSigDB gene sets  
179 within selected collections H, C2, C4, C6. Bioinformatics analysis was performed and  
180 visualized using R version 3.6.1 or Python version 3.7.9. The detailed list of reagents and  
181 kits used in the method can be found in Table S4.

### 182 **Real-time quantitative PCR (RT-qPCR)**

183 Real-time quantitative PCR was performed using Bio-Rad real-time PCR systems. Total  
184 RNA (1  $\mu$ g) was reverse transcribed into cDNA using the Hifair III 1st Strand cDNA  
185 Synthesis SuperMix for qPCR. mRNA expression levels were quantified using Hieff®  
186 qPCR SYBR Green Master Mix, with relative expression calculated by the  $2^{-\Delta\Delta C_t}$  method.  
187 Each sample was tested in triplicate, and primers, reagents and kits are listed in Table S4.

### 188 **IHC Evaluation and Cutoff Determination**

189 Histone expression was quantified using integrated optical density (IOD) values from  
190 Image J (Media Cybernetics Inc., Rockville, MD, USA) analysis[18]. Receiver operating  
191 characteristic (ROC) curve analysis was used to determine cutoff scores for each histone,  
192 distinguishing high and low expression[19]. Clinical features, including age, grade, T  
193 stage, N stage, tumor stage, and receptor status, were classified for analysis. For each  
194 histone biomarker, the point of maximum sensitivity and specificity was selected based  
195 on the area under the curve. Samples were classified as low expression if their integrated  
196 optical density was below the cutoff and high expression if equal to or above the cutoff.  
197 Clinical features used for stratification in ROC analysis included: Age ( $\geq 50$  vs.  $<50$   
198 years), Tumor Grade (Grade 2 vs. 2-3/3), T stage (T1/T2 vs. T3/T4), N stage (N0 vs.  
199 N1/N2), Tumor Stage (Stage I vs. Stage II/III), Receptor Status (ER/PR/HER2 negative  
200 vs. positive), Ki-67 Index ( $<14\%$  vs.  $>14\%$ ). These cutoff values provided a basis for  
201 categorizing histone expression and analyzing its association with breast cancer subtypes  
202 and clinical outcomes.

### 203 **Statistical Analysis**

204 Statistical analyses were conducted using SPSS (v13.0) and GraphPad Prism 9. T-tests,  
205 chi-square tests, and logistic regression were used to analyze data.

### 206 **Results**

#### 207 **Pathological Scoring Identified Key Histone Biomarkers across BC Molecular** 208 **Subtypes**

209 To characterize the global expression of histone biomarkers in tissue samples, IHC  
210 staining was initially performed on two cohorts of BC patients. The analysis included 12

211 histone modifications, 7 histone modifiers, 2 oncohistone mutations, and histone H3 as a  
212 control signal (Fig. 2A). The histone modifications and modifiers selected in this study  
213 are recognized for their roles in driving dysregulated gene expression patterns in breast  
214 cancer (Fig. 2A) and will henceforth be termed histone biomarkers. The first cohort,  
215 referred to as the discovery cohort, comprised 196 tissue spots (Fig. 2B). These were  
216 derived from 98 patients (Table 1), with duplicate spots collected per patient. Each IHC  
217 staining spot was scored by combining the area and density of the dyed region assessed  
218 by Image J. The samples were then categorized into two classes: High-IHC score and  
219 Low-IHC score (Fig. 2C).

220 The molecular subtypes of BC tissues (luminal A, luminal B, HER2-enriched, and TNBC)  
221 in the discovery cohort were determined by analyzing IHC staining patterns for ER, PR,  
222 HER2, and Ki-67 (Fig. 3A). Heatmap of high-IHC % suggests that high-IHC scores are  
223 not uniformly distributed among the molecular subgroups (Figs. 3B & 3C). Statistical  
224 analyses were conducted to assess the significance of the distribution of histone  
225 biomarker levels. Initially, chi-square tests were performed to assess the difference in the  
226 distribution of histone biomarkers across sample subgroups defined by clinical  
227 characteristics as described in Table 1. As presented in Table 2 and Fig 3B, six histone  
228 biomarkers (H3K4me2, H3K9me2, H3K36me2, LSD1, NSD1, and DNMT1) showed  
229 significant differences across the four molecular subtypes. H3K9me2, H3K36me2,  
230 H3K79me (me1/2/3) and two acetylation markers (H3K18ac and H4K16ac) exhibited  
231 significant differences in TNBC compared to other molecular subtypes.

232 Logistic regression analysis was then conducted to explore the relationship between IHC  
233 scores (High-IHC vs. Low-IHC) and histone biomarkers (Table 3), excluding the

234 oncohistone mutations that were not detectable in any of the tissue samples (Fig. S1).  
235 Univariate regression was performed to evaluate the association of each histone  
236 biomarker with the IHC score individually. Histone biomarkers with p-values below 0.05  
237 in the univariate analysis were subsequently included in the multivariate regression  
238 model. The analysis highlighted H3K9me2, H3K36me2, and H3K79me (me1/2/3) as  
239 independent predictors of altered IHC scores in TNBC compared to other molecular  
240 subtypes. G9a, the only histone modifier that exhibited significant differences in TNBC,  
241 was determined to be a dependent predictor. Furthermore, H3K9me2 and H3K36me2,  
242 along with H3K4me2 and others, were also identified as independent predictors for the  
243 luminal A and luminal B subtypes.

#### 244 **Key Histone Biomarkers Serve as Indicators of Advanced Tumorigenesis in BC**

245 Next, we aimed to evaluate the expression levels of selected histone biomarkers in  
246 adjacent healthy breast tissue compared to breast cancer tissue. Due to material  
247 limitations, the analysis focused on histone H3, three specific histone modifications  
248 (H3K4me2, H3K9me2, and H3K9ac), and two corresponding modifiers (G9a and LSD1).  
249 Representative IHC images of luminal A breast cancer and TNBC are displayed side by  
250 side (Fig. 4A). IHC images of two additional independent TNBC predictors, H3K36me2  
251 and H3K79me, are presented alongside LSD1. Histone biomarkers and corresponding  
252 modifiers exhibited clustered expression patterns, as demonstrated in heatmap analyses  
253 (Fig. 3B). Interestingly, histone biomarkers commonly associated with transcriptional  
254 repression (H3K9me2, G9a and LSD1) were more highly expressed in TNBC compared  
255 to luminal A and were also elevated in breast cancer tissue compared to healthy tissue. In  
256 contrast, the expression of biomarkers associated with transcriptional activation

257 (H3K4me2 and H3K9ac) followed a decreasing trend, with the lowest levels observed in  
258 TNBC, intermediate levels in luminal A, and the highest levels in healthy tissue.

259 The MCF-7 cell line treated with estrogen is a well-established luminal A breast cancer  
260 model for studying estrogen-driven regulation. A positive transcriptional response to  
261 estrogen is central to the biology of ER-positive breast cancer and serves as a hallmark of  
262 disease progression and treatment response (Fig. S2). To further explore the identified  
263 key histone biomarkers, their global expression was assessed via ICC staining in  
264 estrogen-treated MCF-7 cells. Notably, the histone biomarkers H3K9me2 and G9a, out of  
265 the five markers characterized above in tissue samples, showed increased expression in  
266 estrogen-treated MCF-7 cells compared to estrogen-deprived cells (Fig. 4B). Additionally,  
267 several other methylation and acetylation markers exhibited altered expression in this  
268 cellular model (Fig. S3), indicating a complex epigenetic landscape in ER-responsive  
269 regulation in breast cancer. These findings reinforce the association of H3K9me2 and  
270 G9a with advanced tumorigenesis in breast cancer and underscore their roles in  
271 promoting estrogen-dependent tumor growth and progression.

## 272 **Validation of Altered Global Histone Modification in TNBC Tissue**

273 As the role of G9a and H3K9me2 in ER-positive breast cancer is better understood, the  
274 focus of this study shifted toward further exploring the significance of key histone  
275 biomarkers in TNBC. To validate these findings, a second breast cancer cohort was  
276 established, comprising 20 tissue slides from 20 TNBC cases. The clinical characteristics  
277 of the validation cohort are summarized, with no significant differences observed  
278 between the discovery and validation cohorts (Table 1). Each tissue sample was stained

279 for 4 histone biomarkers, and the IHC results were scored and classified into IHC-high  
280 and IHC-low categories as described previously (Table 4). The IHC-high percentages of  
281 TNBC-independent predictors (H3K9me2, H3K36me2, H3K79me) and modifier G9a in  
282 the validation cohort are provided in Table 4, alongside corresponding metrics for TNBC  
283 and luminal A cases in the discovery cohort. Significant differences ( $p < 0.05$ ) were  
284 observed in the IHC-high% of all three independent predictors when comparing the at  
285 least one TNBC cohort to luminal A, but no significant difference was found between  
286 validation TNBC and discovery TNBC. This finding confirmed the agreement on the  
287 significance of key histone biomarkers between two TNBC cohorts and further  
288 highlighted the distinction between TNBC and luminal A, in addition to the results  
289 described above comparing TNBC with all non-TNBC subtypes.

290 Among the three histone biomarkers validated in this study, H3K9me2 was selected for  
291 further analysis. One reason for this selection is that while the roles of G9a and  
292 H3K9me2 have been extensively studied in ER-positive breast cancer, their involvement  
293 in TNBC remains largely unexplored, despite strong prior associations. Another reason is  
294 that global H3K9me2 signals were significantly linked to tumor grade, as well as T and N  
295 stages (Table 2, Fig 5A). Notably, a gradual increase in H3K9me2 level (IHC-high%)  
296 was observed with higher tumor grade or stage ( $T4 > T3 > T2$ ) (Fig 5B). This pattern  
297 suggests that H3K9me2 may be associated with more aggressive or advanced breast  
298 cancer status or subtypes, such as TNBC, which are characterized by higher proliferation  
299 rates and poorer clinical outcomes.

300 **G9a Inhibition Disrupts Proliferation and Signaling Pathways in Breast Cancer Cell**  
301 **Lines**

302 UNC0642, a novel small-molecule inhibitor targeting the catalytic activity of G9a, was  
303 evaluated in MCF-7 (luminal A), MDA-MB-231 (claudin-low TNBC), and MDA-MB-  
304 468 (basal-like TNBC) cell lines. Cell viability assays were performed to optimize the  
305 dose and treatment duration (Fig. 6A). Finally, non-cytotoxic concentrations of UNC0642  
306 (2  $\mu$ M) were applied in all subsequent experiments. This inhibitor demonstrated  
307 significant efficacy in reducing H3K9me2 levels in all three cell lines, as confirmed by  
308 both pathological staining and Western blotting analysis (Figs. 6B & 6C). Other histone  
309 modifications, such as H3K4me2, or alternative modifications at the same residue, such  
310 as H3K9ac, remained unaffected, indicating the high specificity of UNC0642.  
311 Interestingly, G9a protein levels were also reduced in basal-like TNBC cells, which  
312 exhibited a more pronounced decrease in H3K9me2 compared to claudin-low TNBC  
313 cells. UNC0642 treatment resulted in marked growth inhibition across all tested cell lines,  
314 with the most significant effects observed in basal-like TNBC cells, followed by claudin-  
315 low TNBC cells, and moderate effects in luminal A cells (Fig. 6D).

316 In line with the expected effects of losing the repressive histone mark H3K9me2, the  
317 number of up-regulated DEGs was 5-fold higher than down-regulated DEGs in two ER-  
318 negative cell lines (Fig. 7A, Fig S4A, Table S1). In contrast, ER-positive MCF-7 cells  
319 showed a balanced number of up- and down-regulated DEGs, aligning with prior reports  
320 that G9a mediate a direct methylation on ER that was functionally linked to breast cancer  
321 progression [17, 20] (Fig. 7A, Fig S4A, Table S1). To further understand the impact of  
322 UNC0642, we performed pathway, GO, and GSEA analyses to evaluate gene group and  
323 pathway-level responses. The results revealed both shared and distinct transcriptional  
324 responses across the three cell lines, highlighting subtype-specific mechanisms of action

325 for the inhibitor (Fig. 7B, Fig S4A). In MCF-7 cells, estrogen-responsive pathways and  
326 gene sets were exclusively down-regulated, supporting previous findings that G9a acts as  
327 an ER $\alpha$  coactivator [17] (Fig. 7C, Fig. S4B, Tables S2 & S3). Interestingly, G9a  
328 inhibition in MDA-MB-231 cells led to a transcriptional response characterized by up-  
329 regulation of oncogenes such as SREBF and down-regulation of tumor suppressor genes  
330 such as TP53, STAT3 and SATB1 (Fig. 7D, Tables S2 & S3). Cell proliferation pathways  
331 and extracellular matrix (ECM)-associated gene sets are consistently down-regulated in  
332 both ER-negative and ER-positive cells, emphasizing the shared growth-suppressive  
333 effects of G9a inhibition and underscoring its significant therapeutic potential across  
334 these breast cancer subtypes (Fig. 7E).

### 335 **Discussion**

336 Significant efforts have been dedicated to systematically profiling histone modifications  
337 and the enzymes that regulate them in ER-positive BC[21]. These studies have been  
338 pivotal in driving the development and clinical application of the first two generations of  
339 epigenetic drugs, such as DNMT inhibitors and HDAC inhibitors, with the third  
340 generation targeting HMTs now emerging. However, similar insights into histone  
341 modification landscapes and their therapeutic potential remain scarce for TNBC, a  
342 subtype known for its aggressive and invasive nature. A greater challenge in developing  
343 epigenetic drugs is their specificity, which requires emphasis on identifying biomarkers  
344 capable of predicting how individual patients will respond to these therapies. This study  
345 aimed to address this critical knowledge gap by unveiling key histone biomarker patterns  
346 in BC with a specific focus on TNBC. Among the >20 histone biomarkers evaluated, our  
347 findings reveal significant alterations in 4 specific histone modification/modifier pairs



348 (H3K4me2/LSD1, H3K9me2/G9a, H3K36me2/NSD1, DNMT1) across the four major  
349 BC molecular subtypes. These findings align with the established evidence supporting  
350 epigenetic therapy in driving ER-positive breast cancer progression[11, 13]. For example,  
351 LSD1 was proposed as a therapeutic target, not only as a standalone approach but also in  
352 combination with hormonal therapies[22]. Given the availability of LSD1 inhibitors in  
353 preclinical and clinical stages, our results further support their exploration as a promising  
354 additional therapy in breast cancer[14, 23].

355 In our analyses with TNBC cohorts, three histone methylation signals (H3K9me2,  
356 H3K36me2, and H3K79me) emerge (and were validated) as independently associated  
357 with TNBC, underscoring their potential role as subtype-specific epigenetic markers and  
358 therapeutic targets. This result aligns with published reports emphasizing the roles of  
359 methylations on H3K36 and H3K79 in TNBC epigenetic regulation. For instance, distinct  
360 patterns of H3K36me3 have been observed in TNBC cell lines, particularly in relation to  
361 androgen receptor pathway activity[7]. Additionally, the chromatin state marked by  
362 H3K4me3 and H3K79me2 at loci such as AFAP1-AS1 has been identified as a hallmark  
363 of TNBC, particularly in driving active transcription programs in these cells[7].  
364 Independent studies have confirmed that both NSD3, a histone methyltransferase  
365 responsible for H3K36me2, and DOT1L, which methylates H3K79, are highly expressed  
366 in the MDA-MB-231 TNBC cell line[24, 25]. Inhibition or knockdown of these histone  
367 writers leads to a reduction in H3K36me2 and H3K79me levels, respectively. This  
368 reduction in histone modifications is associated with a significant decrease in cell  
369 proliferation, migration, and invasion. Notably, in the context of TNBC, these effects are  
370 often linked to the reversal of epithelial-to-mesenchymal transition (EMT), a key process

371 that contributes to increased metastatic potential and the aggressive nature of cancer  
372 cells[26]. Here, our findings provide direct evidence from multiple cohorts of human  
373 tissue to support observations previously made in cell line studies and underscore the  
374 therapeutic potential of targeting histone writers like NSD3 and DOT1L in TNBC  
375 treatment strategies.

376 Mutations in histone H3 (such as H3K36M and H3K27M), so-called “oncohistones”,  
377 have been identified as significant contributors to tumorigenesis in certain cancers and  
378 thus was investigated in this study[27]. H3K36M is known to drive skeletal tumors like  
379 chondroblastoma by dominantly inhibiting H3K36 methylation, leading to transcriptional  
380 dysregulation and altered differentiation[28]. The H3K36M oncohistone primarily  
381 inhibits several H3K36-specific methyltransferases, leading to a reduction in all  
382 methylation states of H3K36[29]. Similarly, the H3K27M mutation disrupts the  
383 repressive H3K27me<sub>3</sub> mark, resulting in widespread epigenetic reprogramming and  
384 aberrant cellular proliferation or tumorigenesis[30]. In our study, neither H3K36M nor  
385 H3K27M mutations were detected in any of the BC tissue samples examined by  
386 histological staining. These findings suggest that while H3 mutations play pivotal roles in  
387 certain malignancies, their contribution to BC pathogenesis, particularly in the context of  
388 our cohort, appears minimal. This highlights the need for further exploration into the  
389 unique histone modification patterns that define BC subtypes.

390 The most substantial finding presented here is that H3K9me<sub>2</sub> deposited by G9a serves as  
391 an independent predictor, with its histological staining results effectively distinguishing  
392 TNBC from other breast cancer subtypes. Furthermore, inhibition of G9a drastically  
393 impairs the proliferation of breast cancer cell lines from various subtypes, including

394 luminal A, claudin-low TNBC and basal-like TNBC, underscoring its potential as a  
395 therapeutic target across these subtypes. Comparing to H3K9me3 that is often linked to  
396 the formation of heterochromatin defining stable and highly repressive chromatin states,  
397 H3K9me2 is less stable, associated with dynamic repression[7]. Its writer G9a has  
398 broader substrate specificity, targeting both histone and non-histone proteins, such as p53,  
399 CDYL, and ER $\alpha$ [31]. G9a is well-recognized as a coactivator in ER-positive breast  
400 cancer, where its inhibition reactivates p53 and induces necroptosis, highlighting its dual  
401 roles in tumor progression[32]. Mechanistically, G9a directly methylates ER $\alpha$ , thereby  
402 enhancing its transcriptional activity on genes that drive cell growth and survival[17].  
403 Experimental depletion of G9a in breast cancer cells and colorectal cancer stem cells has  
404 been shown to suppress motility and disrupt ECM organization, underscoring its broader  
405 role in cancer cell dynamics[33, 34]. Importantly, to our knowledge, our study is the first  
406 transcriptomic analysis profiling TNBC cells after G9a inhibitor treatment, uncovering  
407 pathways that overlap but are not identical to RNAseq result from published G9a-  
408 knockdown experiments[35]. Our transcriptomic analysis of G9a-inhibited BC cells  
409 supports previous findings by revealing G9a's critical role in maintaining ER activity in  
410 ER-positive BC cells and promoting ECM signaling pathways in both ER-positive or -  
411 negative BC cells. While ER signaling is specific to ER-positive cells, EMT pathway  
412 regulation appears consistent across both ER-positive and ER-negative breast cancer cells,  
413 highlighting G9a's broader influence on cellular processes irrespective of estrogen  
414 receptor status[36, 37].

415 Given G9a's involvement in estrogen receptor coactivation, it is considered a potential  
416 therapeutic target for ER-positive breast cancer. However, its epigenetic role in ER-

417 negative breast cancer remains uncertain, given the absence of ER signaling in these  
418 cancers. Notably, the IHC score of H3K9me2 in our cohorts is significantly higher in  
419 higher-grade and later-stage tumors compared to healthy tissue, lower-grade, earlier-stage  
420 or less aggressive subtypes like luminal A. This observation suggests that H3K9me2 may  
421 play a more crucial role in the progression of more aggressive cancers or breast cancer  
422 that doesn't have hormone receptors. Consistent to that, our findings show that G9a  
423 inhibition has a more profound inhibitory effect on cancer growth in basal-like TNBC >  
424 claudin-low TNBC > luminal A BC, highlighting G9a's broader influence across different  
425 BC subtypes via distinct pathways and mechanisms. Additionally, our results reinforce  
426 earlier conclusions that G9a inhibitors induces apoptosis in breast cancer cell lines, with a  
427 more pronounced tumor volume reduction in MDA-MB-231 cells compared to MCF-7  
428 cells[37]. Although cell proliferation was impaired, our transcriptomic profiling revealed  
429 that G9a inhibition in TNBC cell lines uniquely induces the upregulation of oncogene  
430 target genes and the downregulation of genes targeted by tumor suppressors such as  
431 SATB1 and TP53[38, 39]. This contrasts with prior studies that reported G9a inhibitors  
432 effectively suppress tumor growth in preclinical models, though our findings diverge in  
433 terms of the reactivation of silenced tumor suppressor genes[36, 40, 41]. This observation  
434 suggests that the heightened sensitivity of ER-negative breast cancer cells to G9a  
435 inhibitors may be influenced by the epigenetic changes induced by treatment, rather than  
436 reflecting a direct mechanistic basis.

437 This study, while providing valuable insights, has several limitations that warrant  
438 consideration. The relatively small cohort size and lack of follow-up or survival data  
439 impede a comprehensive understanding of the prognostic value of histone biomarkers.

440 Additionally, the scoring methodology, reliant on manual assessment, requires significant  
441 labor, experienced technicians, and carries the risk of manual error, emphasizing the need  
442 for automation through machine learning-driven imaging technology. Furthermore, the  
443 absence of in vivo validation limits the ability to confirm the therapeutic potential of G9a  
444 inhibitors, highlighting the need for preclinical studies and further investigation into its  
445 dualistic functions in breast cancer subtypes.

#### 446 **Conclusion**

447 The immunohistochemical profiling and transcriptomic analyses presented in this study  
448 identify effective subtype-specific epigenetic targets in various BC subtypes, with a  
449 particular focus on TNBC. The findings highlight G9a's multifaceted role in regulating  
450 both hormone-driven pathways and tumor suppressor mechanisms, demonstrating its  
451 context-dependent influence. This research sheds light on the epigenetic complexity  
452 underlying TNBC and provides valuable insights for developing targeted therapeutic  
453 strategies, offering a promising avenue to improve outcomes for patients with this  
454 challenging breast cancer subtype.

#### 455 **Consent for publication**

456 All authors have read the manuscript and are consentaneous for publication.

#### 457 **Funding**

458 This work was supported by National Natural Science Foundation of China (81672627;  
459 82071863).

#### 460 **Author contributions**

461 XZ conceptualized the study design and the workflow, supervised all aspects of the  
462 research, drafted figures and finalized the manuscript. ZH and SZ conducted experiments  
463 (except those otherwise noted), processed samples, analyzed data, prepared illustrations,  
464 and contributed to manuscript preparation. GS performed IHC staining for the discovery  
465 cohort. YC supported the manuscript drafting and provided critical feedback. RC  
466 developed the bioinformatics analysis pipeline. MJ, DY, and SZ offered supports on  
467 drafting experimental protocols and performing statistical analysis. YX assisted with  
468 experiment design, supervised the experiments, and critically reviewed the manuscript.

#### 469 **Acknowledgments**

470 We extend our gratitude to the commercial organizations and their patient contributors for  
471 providing the tissue samples used in this study.

#### 472 **Competing interests**

473 The authors have declared that no conflict of interest exists.

#### 474 **Availability of data and materials**

475 Raw and processed files for RNA sequences (FASTQ format) supporting the findings of  
476 this study have been deposited in the National Center for Biotechnology Information  
477 (NCBI) Gene Expression Omnibus (GEO) under accession number GSE283819.

478

479 **Reference**

- 480 1. Bannister, A.J. and T. Kouzarides, *Regulation of chromatin by histone modifications*. Cell  
481 Res, 2011. **21**(3): p. 381-95.
- 482 2. Yang, Y., M. Zhang, and Y. Wang, *The roles of histone modifications in tumorigenesis and*  
483 *associated inhibitors in cancer therapy*. J Natl Cancer Cent, 2022. **2**(4): p. 277-290.
- 484 3. Zhang, X., H. Wen, and X. Shi, *Lysine methylation: beyond histones*. Acta Biochim Biophys  
485 Sin (Shanghai), 2012. **44**(1): p. 14-27.
- 486 4. Beňačka, R., et al., *Classic and New Markers in Diagnostics and Classification of Breast*  
487 *Cancer*. Cancers (Basel), 2022. **14**(21).
- 488 5. Eccles, S.A., et al., *Critical research gaps and translational priorities for the successful*  
489 *prevention and treatment of breast cancer*. Breast Cancer Res, 2013. **15**(5): p. R92.
- 490 6. Zhuang, J., et al., *Perspectives on the Role of Histone Modification in Breast Cancer*  
491 *Progression and the Advanced Technological Tools to Study Epigenetic Determinants of*  
492 *Metastasis*. Front Genet, 2020. **11**: p. 603552.
- 493 7. Xi, Y., et al., *Histone modification profiling in breast cancer cell lines highlights*  
494 *commonalities and differences among subtypes*. BMC Genomics, 2018. **19**(1): p. 150.
- 495 8. Borkiewicz, L., *Histone 3 Lysine 27 Trimethylation Signature in Breast Cancer*. Int J Mol Sci,  
496 2021. **22**(23).
- 497 9. Li, W., et al., *Targeting Histone Modifications in Breast Cancer: A Precise Weapon on the*  
498 *Way*. Front Cell Dev Biol, 2021. **9**: p. 736935.
- 499 10. Cheng, Y., et al., *Targeting epigenetic regulators for cancer therapy: mechanisms and*  
500 *advances in clinical trials*. Signal Transduct Target Ther, 2019. **4**: p. 62.
- 501 11. Marzochi, L.L., et al., *Use of histone methyltransferase inhibitors in cancer treatment: A*  
502 *systematic review*. Eur J Pharmacol, 2023. **944**: p. 175590.
- 503 12. White, J., et al., *Histone lysine acetyltransferase inhibitors: an emerging class of drugs for*  
504 *cancer therapy*. Trends Pharmacol Sci, 2024. **45**(3): p. 243-254.
- 505 13. Liao, Q., et al., *Novel insights into histone lysine methyltransferases in cancer therapy:*  
506 *From epigenetic regulation to selective drugs*. J Pharm Anal, 2023. **13**(2): p. 127-141.
- 507 14. Gold, S. and A. Shilatifard, *Epigenetic therapies targeting histone lysine methylation:*  
508 *complex mechanisms and clinical challenges*. J Clin Invest, 2024. **134**(20).
- 509 15. Feng, J. and X. Meng, *Histone modification and histone modification-targeted anti-*  
510 *cancer drugs in breast cancer: Fundamentals and beyond*. Front Pharmacol, 2022. **13**: p.  
511 946811.
- 512 16. Zhang, X., et al., *Regulation of estrogen receptor  $\alpha$  by histone methyltransferase SMYD2-*  
513 *mediated protein methylation*. Proc Natl Acad Sci U S A, 2013. **110**(43): p. 17284-9.
- 514 17. Zhang, X., et al., *G9a-mediated methylation of ER $\alpha$  links the PHF20/MOF histone*  
515 *acetyltransferase complex to hormonal gene expression*. Nat Commun, 2016. **7**: p. 10810.
- 516 18. Chen, Y., et al., *MicroRNA-133b is regulated by TAp63 while no gene mutation is present*  
517 *in colorectal cancer*. Oncol Rep, 2017. **37**(3): p. 1646-1652.
- 518 19. Fang, Y., et al., *Protein expression of ZEB2 in renal cell carcinoma and its prognostic*  
519 *significance in patient survival*. PLoS One, 2013. **8**(5): p. e62558.
- 520 20. Vini, R., et al., *27-Hydroxycholesterol represses G9a expression via oestrogen receptor*  
521 *alpha in breast cancer*. J Cell Mol Med, 2023. **27**(18): p. 2744-2755.
- 522 21. Garcia-Martinez, L., et al., *Epigenetic mechanisms in breast cancer therapy and*  
523 *resistance*. Nat Commun, 2021. **12**(1): p. 1786.


- 524 22. Prasanna, T., et al., *A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1*  
525 *Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED)*. Front  
526 *Oncol*, 2022. **12**: p. 862427.
- 527 23. Noce, B., et al., *LSD1 inhibitors for cancer treatment: Focus on multi-target agents and*  
528 *compounds in clinical trials*. Front Pharmacol, 2023. **14**: p. 1120911.
- 529 24. Byun, W.S., et al., *Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A*  
530 *Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer*. Mol Ther  
531 *Oncolytics*, 2019. **15**: p. 140-152.
- 532 25. Jeong, G.Y., et al., *NSD3-Induced Methylation of H3K36 Activates NOTCH Signaling to*  
533 *Drive Breast Tumor Initiation and Metastatic Progression*. Cancer Res, 2021. **81**(1): p. 77-  
534 90.
- 535 26. Grasset, E.M., et al., *Triple-negative breast cancer metastasis involves complex epithelial-*  
536 *mesenchymal transition dynamics and requires vimentin*. Sci Transl Med, 2022. **14**(656):  
537 p. eabn7571.
- 538 27. Sahu, V. and C. Lu, *Oncohistones: Hijacking the histone code*. Annu Rev Cancer Biol, 2022.  
539 **6**: p. 293-312.
- 540 28. Fang, D., et al., *The histone H3.3K36M mutation reprograms the epigenome of*  
541 *chondroblastomas*. Science, 2016. **352**(6291): p. 1344-8.
- 542 29. Rajagopalan, K.N., et al., *Depletion of H3K36me2 recapitulates epigenomic and*  
543 *phenotypic changes induced by the H3.3K36M oncohistone mutation*. Proc Natl Acad Sci  
544 U S A, 2021. **118**(9).
- 545 30. Harutyunyan, A.S., et al., *H3K27M induces defective chromatin spread of PRC2-mediated*  
546 *repressive H3K27me2/me3 and is essential for glioma tumorigenesis*. Nat Commun,  
547 2019. **10**(1): p. 1262.
- 548 31. Zhang, X., Y. Huang, and X. Shi, *Emerging roles of lysine methylation on non-histone*  
549 *proteins*. Cell Mol Life Sci, 2015. **72**(22): p. 4257-72.
- 550 32. Mabe, N.W., et al., *G9a Promotes Breast Cancer Recurrence through Repression of a Pro-*  
551 *inflammatory Program*. Cell Rep, 2020. **33**(5): p. 108341.
- 552 33. Jin, Y., et al., *G9a Knockdown Suppresses Cancer Aggressiveness by Facilitating Smad*  
553 *Protein Phosphorylation through Increasing BMP5 Expression in Luminal A Type Breast*  
554 *Cancer*. Int J Mol Sci, 2022. **23**(2).
- 555 34. Bergin, C.J., et al., *G9a controls pluripotent-like identity and tumor-initiating function in*  
556 *human colorectal cancer*. Oncogene, 2021. **40**(6): p. 1191-1202.
- 557 35. Kim, K., et al., *RNA-seq based transcriptome analysis of EHMT2 functions in breast cancer*.  
558 *Biochem Biophys Res Commun*, 2020. **524**(3): p. 672-676.
- 559 36. Liu, X.R., et al., *UNC0638, a G9a inhibitor, suppresses epithelial-mesenchymal*  
560 *transition-mediated cellular migration and invasion in triple negative breast cancer*. Mol  
561 *Med Rep*, 2018. **17**(2): p. 2239-2244.
- 562 37. Dong, C., et al., *G9a interacts with Snail and is critical for Snail-mediated E-cadherin*  
563 *repression in human breast cancer*. J Clin Invest, 2012. **122**(4): p. 1469-86.
- 564 38. Han, H.J., et al., *SATB1 reprogrammes gene expression to promote breast tumour growth*  
565 *and metastasis*. Nature, 2008. **452**(7184): p. 187-93.
- 566 39. Silwal-Pandit, L., et al., *TP53 mutation spectrum in breast cancer is subtype specific and*  
567 *has distinct prognostic relevance*. Clin Cancer Res, 2014. **20**(13): p. 3569-80.
- 568 40. Zhang, Q., et al., *Discovery of novel G9a/GLP covalent inhibitors for the treatment of*  
569 *triple-negative breast cancer*. Eur J Med Chem, 2023. **261**: p. 115841.



570 41. Casciello, F., et al., *G9a-mediated repression of CDH10 in hypoxia enhances breast*  
571 *tumour cell motility and associates with poor survival outcome*. *Theranostics*, 2020.  
572 **10**(10): p. 4515-4529.

573

Fig. 1




**Fig. 2**


**A**

Histone Mod.	Transcriptional Reg.	Role in BC	High-IHC %
H3K4me2	Activation	Promotes growth	71.43
H3K9me2	Repression	Represses growth	40.82
H3K9ac	Activation	Promotes growth	19.39
H3K18ac	Activation	Promotes growth	70.41
H3K27me3	Repression	Represses growth	25.00
H3K27ac	Activation	Promotes growth	50.00
H3K36me2	Activation	Represses growth	50.51
H3K79me1/2/3	Activation	Promotes growth	31.12
H4K12ac	Activation	Promotes growth	37.24
H4K16ac	Activation	Represses growth	32.65
H4K20me3	Repression	Represses growth	61.73
H4R3me2	Dual Roles	Promotes growth	33.16
Methyltransferase	Histone Target	Role in BC	High-IHC %
DNMT1	DNA	Oncogene	42.86
G9a/EHMT2	H3K9me1/2	Oncogene	12.62
EZH2	H3K27me3	Oncogene	66.33
SMYD2/KMT3C	H3K36me1/2	Oncogene	58.67
NSD1/KMT3B	H3K36me2/3	Dual roles	56.12
Demethylase	Histone Target	Role in BC	High-IHC %
LSD1	H3K4/9me1/2	Oncogene	69.39
KDM3A/JHDM2A	H3K9me1/2	Oncogene	12.76
Histone Mutation	Impact	Role in Cancer	
H3K27M	H3K27me3 loss	Promotes growth	
H3K36M	H3K27me1/2/3 loss	Promotes growth	




**B**




**C**



**Fig. 3**




**Fig. 4**





**Fig. 5**

**A**



**B**



**Fig. 6**







**Fig. 7****A****B****C****D****E**



Fig. S1




Fig. S2








Fig. S3



**Fig. S4**

**A**



**B**

